Clinical Trial Update: Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of imatinib mesylate and paclitaxel in recurrent ovarian cancer and Mullerian-origin cancers was terminated; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Gleevec (Imatinib)
• Taxol (paclitaxel)

Snippet

Sponsor: NYU Langone Health | Conditions: Ovarian Cancer | Phase 2 | Status: TERMINATED | Results posted: 2011-09-26